Payment overview · 2025
General Payments
$237.12
13 reported records · 6 companies
Healthcare provider profile · identity verified
Bryan Anthony Picou, M.D
Allopathic & Osteopathic Physicians|Family Medicine · NATCHITOCHES, LA · NPI 1922003656
Verified facts
What the public records show
CMS Open Payments records show Bryan Anthony Picou, M.D received $237.12 in general payments during 2025 across 13 reported records.
Xeris Pharmaceuticals, Inc. accounted for 33.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $80.36 | 33.9% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $53.88 | 22.7% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $35.79 | 15.1% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $35.64 | 15.0% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.10 | 6.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.35 | 6.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $237.12 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $59.80 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $35.64 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $32.51 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $21.37 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $20.56 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $16.10 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $16.10 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 113 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 99 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 92 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
99 | 21 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
92 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
113 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 627 | 145 |
| Amlodipine Besylate | Amlodipine Besylate | 476 | 103 |
| Gabapentin | Gabapentin | 384 | 83 |
| Famotidine | Famotidine | 359 | 38 |
| Levothyroxine Sodium | Levothyroxine Sodium | 345 | 66 |
| Losartan Potassium | Losartan Potassium | 319 | 45 |
| Lisinopril | Lisinopril | 300 | 69 |
| Potassium Chloride | Potassium Chloride | 279 | 57 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 272 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 245 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 230 | 49 |
| Sertraline Hcl | Sertraline Hcl | 222 | 29 |
| Furosemide | Furosemide | 201 | 37 |
| Metformin Hcl | Metformin Hcl | 199 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 195 | 51 |
| Simvastatin | Simvastatin | 151 | 32 |
| Carvedilol | Carvedilol | 147 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 139 | 27 |
| Memantine Hcl | Memantine Hcl | 137 | 12 |
| Trulicity | Dulaglutide | 131 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 130 | 43 |
| Tramadol Hcl | Tramadol Hcl | 130 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 124 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 123 | 20 |
| Alprazolam | Alprazolam | 122 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 122 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 121 | 24 |
| Omeprazole | Omeprazole | 118 | 33 |
| Clonazepam | Clonazepam | 115 | 13 |
| Eliquis | Apixaban | 113 | 21 |
| Mirtazapine | Mirtazapine | 109 | suppressed |
| Ezetimibe | Ezetimibe | 105 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 101 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 99 | 23 |
| Farxiga | Dapagliflozin Propanediol | 99 | 21 |
| Donepezil Hcl | Donepezil Hcl | 97 | 14 |
| Jardiance | Empagliflozin | 92 | 24 |
| Metformin Hcl Er | Metformin Hcl | 91 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 90 | 16 |
| Primidone | Primidone | 81 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 80 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 80 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 79 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 78 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 77 | 19 |
| Alendronate Sodium | Alendronate Sodium | 76 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 75 | suppressed |
| Ozempic | Semaglutide | 74 | 12 |
| Nateglinide | Nateglinide | 73 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 69 | 11 |
| Levetiracetam | Levetiracetam | 67 | suppressed |
| Prednisone | Prednisone | 66 | 54 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 63 | 12 |
| Valsartan | Valsartan | 62 | 13 |
| Vascepa | Icosapent Ethyl | 61 | 11 |
| Montelukast Sodium | Montelukast Sodium | 60 | 19 |
| Pregabalin | Pregabalin | 59 | suppressed |
| Lorazepam | Lorazepam | 58 | 12 |
| Nifedipine Er | Nifedipine | 58 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 58 | suppressed |
| Allopurinol | Allopurinol | 55 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 11 |
| Divalproex Sodium | Divalproex Sodium | 54 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 52 | suppressed |
| Irbesartan | Irbesartan | 52 | suppressed |
| Spironolactone | Spironolactone | 52 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 49 | suppressed |
| Myrbetriq | Mirabegron | 48 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 48 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 48 | 16 |
| Trintellix | Vortioxetine Hydrobromide | 46 | suppressed |
| Naproxen | Naproxen | 45 | 14 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 45 | 38 |
| Morphine Sulfate Er | Morphine Sulfate | 44 | suppressed |
| Amoxicillin | Amoxicillin | 43 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | suppressed |
| Ibuprofen | Ibuprofen | 42 | 11 |
| Mounjaro | Tirzepatide | 42 | suppressed |
| Bupropion Xl | Bupropion Hcl | 41 | suppressed |
| Methadone Hcl | Methadone Hcl | 41 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 39 | suppressed |
| Haloperidol | Haloperidol | 39 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 39 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 38 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 38 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 37 | suppressed |
| Methocarbamol | Methocarbamol | 37 | 14 |
| Finasteride | Finasteride | 36 | suppressed |
| Azithromycin | Azithromycin | 35 | 25 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 31 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 34 | 34 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 14 |
| Rybelsus | Semaglutide | 32 | suppressed |
| Fluconazole | Fluconazole | 31 | 18 |
| Meloxicam | Meloxicam | 31 | 14 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 31 | suppressed |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 30 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 30 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 30 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 29 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 28 | suppressed |
| Niacin Er | Niacin | 28 | suppressed |
| Torsemide | Torsemide | 28 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 27 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Lamotrigine | Lamotrigine | 27 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 25 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 25 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Ketoconazole | Ketoconazole | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 22 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 22 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Latanoprost | Latanoprost | 21 | suppressed |
| Metolazone | Metolazone | 21 | suppressed |
| Telmisartan | Telmisartan | 21 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 19 | 16 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Rivastigmine | Rivastigmine | 19 | suppressed |
| Clonidine | Clonidine | 18 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 16 |
| Indapamide | Indapamide | 17 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Cyclosporine | Cyclosporine | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Minoxidil | Minoxidil | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 15 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Phenytoin | Phenytoin | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 14 | 12 |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Hydroxyurea | Hydroxyurea | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Multaq | Dronedarone Hcl | 12 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Trimethoprim | Trimethoprim | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Acetazolamide | Acetazolamide | 11 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Probenecid | Probenecid | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $237.12 · 13 records | Xeris Pharmaceuticals, Inc. | ABRYSVO, BREZTRI, COMIRNATY, ELIQUIS, FARXIGA, GVOKE HYPOPEN, JARDIANCE, KEVEYIS, Kerendia, NURTEC ODT, NUZYRA, PREVNAR 20, XHANCE | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error